The global subcutaneous biologic market size was valued at USD 250.83 billion in 2025 and is projected to grow from USD 279.68 billion in 2026 to USD 676.58 billion by 2034, registering a CAGR of 11.68% during the forecast period (2026–2034). North America dominated the subcutaneous biologic market with a market share of 51.02% in 2025.
Subcutaneous biologics are injectable therapeutic products administered beneath the skin to deliver monoclonal antibodies, hormones, and other biologic drugs for treating chronic and complex diseases. These formulations provide convenient administration compared with intravenous therapies, enabling faster treatment and greater flexibility in clinical and homecare settings.
The subcutaneous biologic market demand is driven by the rising prevalence of chronic diseases, growing preference for self-administration, and expanding availability of advanced biologic therapies. Technological advancements in drug delivery systems, increasing biologic approvals, and expanding healthcare infrastructure are also contributing to subcutaneous biologic market growth.
Download a Free Sample To learn more about this report,
The subcutaneous biologic market is moderately exposed to supply chain disruptions due to its dependence on complex biologic manufacturing processes, cold-chain logistics, specialized raw materials, and sterile packaging components. Disruptions in the supply of active pharmaceutical ingredients, single-use bioprocessing materials, syringes, and temperature-controlled transportation can delay production schedules and product availability across global markets. The market is experiencing a capacity-constrained recovery, with production and distribution gradually stabilizing as manufacturers expand manufacturing capacity, secure critical supply sources, and optimize global logistics networks.
Growing Adoption of Self-administration with Advanced Drug Delivery Devices
The increasing preference for home-based treatment is accelerating the transition from hospital-administered intravenous biologics to subcutaneous formulations supported by user-friendly drug delivery devices. This shift is improving patient convenience, reducing healthcare facility visits, and enhancing treatment adherence for chronic disease management. Pharmaceutical companies are increasingly developing biologics compatible with autoinjectors and wearable injectors to simplify administration.
Expansion of High-concentration Biologic Formulations for Faster Drug Administration
The growing demand for shorter treatment times is driving the transition toward high-concentration, low-volume subcutaneous biologic formulations. These innovations enable rapid drug delivery while maintaining therapeutic efficacy, improving patient experience and healthcare workflow efficiency. Manufacturers are investing in formulation technologies that support larger biologic doses through subcutaneous injection without compromising safety.
The subcutaneous biologic market forecasts continued investment activity driven by increasing biologic drug adoption and rising demand for advanced drug delivery technologies.
Key Investment and Funding Activities in Subcutaneous Biologic Market, 2025
F. Hoffmann-La Roche Ltd.
Up to USD 550 million
In May 2025, Roche announced an investment of up to USD 550 million to expand its Indianapolis manufacturing hub, strengthening production capacity for advanced injectable healthcare technologies and supporting long-term biologics manufacturing expansion.
Novo Nordisk
USD 9.5 billion
During 2025, Novo Nordisk continued major investments in manufacturing capacity, R&D infrastructure, and production expansion to meet growing global demand for injectable biologic therapies, including subcutaneous GLP-1 products.
Rising Prevalence of Rheumatoid Arthritis and Growing Adoption of Recombinant Human Hyaluronidase Technology Drives Market
The increasing prevalence of chronic diseases such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, psoriasis, and various cancers is driving demand for subcutaneous biologics worldwide. Growing patient populations are increasing the need for targeted biologic therapies that offer improved efficacy and long-term disease management. This is encouraging pharmaceutical companies to expand their biologic portfolios and develop subcutaneous formulations for broader patient access.
The increasing integration of recombinant human hyaluronidase (rHuPH20) technology is driving the development of high-volume subcutaneous biologics by enabling rapid delivery of larger drug doses through subcutaneous injection. This technology supports the conversion of intravenous biologics into subcutaneous formulations while maintaining therapeutic efficacy. Roche's Phesgo and Bristol Myers Squibb's Opdivo Qvantig utilize Halozyme's ENHANZE (rHuPH20) technology.
Complex Cold Chain Storage and Formulation Complexity Restrain Market Expansion
Subcutaneous biologics require stringent cold chain storage, temperature-controlled transportation, and specialized handling throughout the supply chain to maintain product stability and efficacy. Any deviation during storage or distribution can compromise product quality, resulting in wastage and supply interruptions.
Developing subcutaneous formulations for high-dose biologics requires advanced formulation technologies to achieve adequate drug concentration, stability, and injectability within limited injection volumes. Many biologics cannot be easily reformulated for subcutaneous administration without specialized delivery technologies or excipients.
Expansion of Contract Development and Manufacturing and Biologic Patent Expirations Offer Growth Opportunities to Market Players
The increasing outsourcing of biologic formulation, fill-finish, and aseptic manufacturing is creating strong growth opportunities for CDMOs specializing in subcutaneous biologics. Pharmaceutical companies are partnering with specialized manufacturers to accelerate product commercialization, reduce capital expenditure, and expand production capacity. This opportunity particularly benefits CDMOs and technology providers investing in high-potency biologics and sterile injectable manufacturing.
The wave of biologic patent expirations is creating significant opportunities for biosimilar manufacturers to launch subcutaneous alternatives with improved accessibility and competitive pricing. Companies can leverage established clinical evidence while developing differentiated subcutaneous delivery formats to gain market share across immunology, oncology, and inflammatory diseases. This opportunity benefits biosimilar developers, pharmaceutical companies, and healthcare providers seeking cost-effective treatment options.
Achieving Interchangeability and Managing Immunogenicity Challenges Market Growth
Expanding the adoption of subcutaneous biosimilars remains challenging as physicians often prefer established reference biologics for patients requiring long-term therapy. Variations in prescribing practices, switching policies, and clinical confidence slow the uptake of newer products despite regulatory approvals.
Maintaining consistent immunogenicity profiles and minimizing injection-site reactions remain major challenges as more biologics are reformulated for subcutaneous administration. Differences in formulation, excipients, and dosing frequency can influence patient acceptance and long-term treatment adherence.
Request Customizationto receive a tailored report.
The monoclonal antibodies segment accounted for a share of 48.76% in 2025, as monoclonal antibodies dominate commercial biologic pipelines and have the highest number of approved subcutaneous formulations. Lifecycle management strategies converting blockbuster intravenous therapies into subcutaneous versions further strengthened their market leadership.
The oligonucleotide segment is expected to grow at a CAGR of around 12.46% during the forecast period due to increasing clinical advancement of RNA-based therapeutics and improving conjugation technologies. Expanding pipelines for rare genetic and cardiometabolic diseases are accelerating commercialization opportunities within this emerging molecule class.
In 2025, prefilled syringes accounted for a share of 68.93%, as they provide high dosing accuracy and broad regulatory acceptance for established subcutaneous biologics. Their widespread integration into healthcare settings continues supporting dominant market utilization across therapeutic applications.
The wearable injectors segment is expected to grow at a CAGR of 12.69% during the forecast period, driven by increasing development of ultra-high-volume biologic formulations requiring prolonged subcutaneous infusion beyond manual injection capability.
The autoimmune & inflammatory segment accounted for a share of 38.75% in 2025, as continuous maintenance therapy requirements and broad availability of self-administered biologics targeting chronic immune-mediated disorders. High patient retention on long-duration biologic treatment supported sustained prescription volumes and recurring product demand.
The oncology & hematology segment is expected to grow at a CAGR of 13.06% during the forecast period, driven by the increasing development of fixed-dose subcutaneous cancer biologics replacing weight-based intravenous administration for selected therapies.
Speak to an Analystto discuss market opportunities.
North America: Market Dominance Led by Strong Biologic Innovation and Rapid Adoption of Subcutaneous Drug Delivery
The North America subcutaneous biologic market accounted for the largest regional share of 51.02% in 2025, driven by strong biologics innovation, rapid adoption of subcutaneous formulations, and extensive commercialization of self-administered therapies across oncology, immunology, and metabolic disorders. The region also benefits from advanced biologics manufacturing capabilities, favorable regulatory pathways, and high healthcare expenditure.
The US subcutaneous biologic market was valued at USD 111.59 billion in 2025, driven by increasing regulatory approvals for subcutaneous biologics, growing adoption of self-injectable therapies, and strong investments in biologic research and manufacturing. In 2025, the US FDA approved 46 novel drugs, including multiple therapeutic biologics, reflecting the region's strong biologics innovation ecosystem and continued expansion of advanced biologic therapies.
The subcutaneous biologic market in Canada was valued at USD 16.38 billion in 2025, supported by expanding access to biologic therapies, increasing adoption of biosimilars, and growing preference for home-based treatment. The country's universal healthcare system, expanding reimbursement for biologics, and increasing use of specialty medicines continue to create favorable conditions for sustained market growth.
Asia Pacific: Fastest Growth Driven by Expanding Biopharmaceutical Manufacturing and Increasing Adoption of Self-Administered Biologics
The Asia Pacific subcutaneous biologic market is expected to grow at a CAGR of 13.51% during the forecast period, showcasing the fastest regional growth. Growth is supported by expanding biopharmaceutical manufacturing capacity, increasing adoption of self-administered biologics, and improving access to advanced specialty therapies.
The China subcutaneous biologic market was valued at USD 12.27 billion in 2025, supported by rapid expansion of domestic biologic manufacturing, increasing commercialization of innovative monoclonal antibodies, and growing investment in biopharmaceutical research. The country's expanding biotechnology sector and rising prevalence of chronic diseases continue to strengthen demand for subcutaneous biologics.
The India subcutaneous biologic market was valued at USD 6.27 billion in 2025, fueled by increasing availability of biologics through specialty pharmacy networks and the growing adoption of day-care treatment models for chronic diseases. The expansion of private infusion centers and wider physician acceptance of subcutaneous biologic formulations are improving treatment accessibility beyond metropolitan areas.
The Japan subcutaneous biologic market was valued at USD 7.24 billion in 2025, supported by growing adoption of innovative biologics for oncology and autoimmune diseases, coupled with strong regulatory support for advanced pharmaceutical products. The country's mature biopharmaceutical industry and growing elderly population continue to support sustained demand for subcutaneous biologic therapies.
Unlock Regional Insightsto access country-level data, & regional trends.
The subcutaneous biologic market competitive landscape is moderately consolidated, with competition led by global biopharmaceutical companies, biologic developers, and drug delivery technology providers. Leading players compete through innovative biologic formulations, proprietary subcutaneous delivery platforms, and lifecycle management strategies. The subcutaneous biologic market ecosystem is shaped by increasing biologic approvals, advances in drug delivery technologies, and strategic licensing collaborations.
September 2025: F. Hoffmann-La Roche Ltd. announced that the European Medicines Agency's CHMP recommended approval of the subcutaneous formulation of Lunsumio (mosunetuzumab) for relapsed or refractory follicular lymphoma, supporting expansion of its subcutaneous hematology portfolio.
September 2025: Merck & Co., Inc. received US FDA approval for Keytruda Qlex (pembrolizumab and berahyaluronidase alfa) for subcutaneous injection across approved intravenous Keytruda solid tumor indications.
Customize This Report to Match Your Strategic Objectives
Author's Details
Senior Research Associate
Dhanashri Bhapakar is a Senior Research Associate with 3+ years of experience in the Biotechnology sector. She focuses on tracking innovation trends, R&D breakthroughs, and market opportunities within biopharmaceuticals and life sciences. Dhanashri’s deep industry knowledge enables her to provide precise, data-backed insights that help companies innovate and compete effectively in global biotech markets.
We are featured on:
sales@straitsresearch.com